Kura Oncology to Report First Quarter 2026 Financial Results

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. A live webcast and archived replay will be available on the company Investors website.

News Market Reaction – KURA

+0.43%

+0.43% Session close to close

In the May 5 session, KURA gained 0.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the schedule for Kura Oncology’s first-quarter 2026 financial results and a m...

Analysis

This announcement sets the schedule for Kura Oncology’s first-quarter 2026 financial results and a management webcast, continuing its pattern of structured communication around earnings. The prior earnings-date notice was followed by a modest +1.05% move. With the stock trading above its $8.93 200‑day moving average yet below the $12.49 52-week high, attention will turn to Q1 figures, commercial progress for KOMZIFTI, and pipeline updates as key markers for the next phase of the story.

Key Figures

Earnings date: May 12, 2026 Conference call time: 4:30 p.m. ET / 1:30 p.m. PT Share price: $9.25 +3 more

6 metrics

Earnings date May 12, 2026 Q1 2026 financial results to be reported after U.S. market close

Conference call time 4:30 p.m. ET / 1:30 p.m. PT Management webcast and call to discuss Q1 2026 results

Share price $9.25 Price prior to Q1 2026 earnings date announcement

Daily price move 5.47% Change over the last 24 hours before this news

52-week range $5.45 – $12.49 Low and high over the past 52 weeks

Market capitalization $778,448,914 Equity value prior to Q1 2026 earnings date news

Previous Earnings date Reports

1 past event · Latest: Feb 26 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Earnings date notice	Neutral	+1.1%	Set date and call details for Q4 and full‑year 2025 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date scheduling news for KURA was followed by a modest positive move, indicating that simple timing announcements have historically drawn a measured, positive reaction.

Recent Company History

Recent Kura Oncology news has centered on both clinical progress and the transition to a commercial-stage company. In February 2026, an earnings date announcement for Q4 and full-year 2025 preceded a modest +1.05% move. Subsequent updates highlighted KOMZIFTI’s FDA approval, initial product revenue, and a strong cash position, alongside promising darlifarnib combination data in ccRCC. Today’s first‑quarter 2026 earnings date notice fits this pattern of structured communication around financial updates and pipeline progress.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.

The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When will Kura Oncology (KURA) report Q1 2026 financial results?

Kura Oncology will report Q1 2026 results after U.S. markets close on Tuesday, May 12, 2026. According to Kura Oncology, management will release results and host a webcast and conference call the same day to discuss the financials and corporate update.

What time is the Kura Oncology (KURA) earnings webcast and call on May 12, 2026?

The webcast and conference call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on May 12, 2026. According to Kura Oncology, the event will cover the quarter results and provide a corporate update for investors and analysts.

Where can I access the live webcast and replay for Kura Oncology (KURA) Q1 2026 results?

The live webcast and archived replay will be available on the company's Investors section at www.kuraoncology.com. According to Kura Oncology, both the live stream and replay can be accessed from the investor relations web page.

Will Kura Oncology (KURA) management discuss corporate updates during the Q1 2026 call?

Yes. Management will discuss the financial results and provide a corporate update during the May 12, 2026 call. According to Kura Oncology, the session is intended to review quarterly performance and share any relevant corporate developments.

How can investors participate in the Kura Oncology (KURA) May 12, 2026 conference call?

Investors can join the live webcast via the Investors section of the company website at www.kuraoncology.com. According to Kura Oncology, the webcast link will provide live access and an archived replay after the event.